{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "from IPython.display import Image, display\n",
    "from langgraph.graph import END, START, StateGraph\n",
    "from typing_extensions import TypedDict\n",
    "from _constants import LLM_CONFIGS\n",
    "from langchain_ollama import ChatOllama\n",
    "from langchain_core.messages import HumanMessage, SystemMessage\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Example - Prompt Chaining"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Graph state\n",
    "class State(TypedDict):\n",
    "    topic: str\n",
    "    joke: str\n",
    "    improved_joke: str\n",
    "    final_joke: str"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "llm = ChatOllama(\n",
    "    model=LLM_CONFIGS[\"llama3.2\"][\"model\"]\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<IPython.core.display.Image object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Nodes\n",
    "def generate_joke(state: State):\n",
    "    \"\"\"First LLM call to generate initial joke\"\"\"\n",
    "\n",
    "    msg = llm.invoke(f\"Write a short joke about {state['topic']}\")\n",
    "    return {\"joke\": msg.content}\n",
    "\n",
    "\n",
    "def check_punchline(state: State):\n",
    "    \"\"\"Gate function to check if the joke has a punchline\"\"\"\n",
    "\n",
    "    # Simple check - does the joke contain \"?\" or \"!\"\n",
    "    if \"?\" in state[\"joke\"] or \"!\" in state[\"joke\"]:\n",
    "        return \"Fail\"\n",
    "    return \"Pass\"\n",
    "\n",
    "\n",
    "def improve_joke(state: State):\n",
    "    \"\"\"Second LLM call to improve the joke\"\"\"\n",
    "\n",
    "    msg = llm.invoke(f\"Make this joke funnier by adding wordplay: {state['joke']}\")\n",
    "    return {\"improved_joke\": msg.content}\n",
    "\n",
    "\n",
    "def polish_joke(state: State):\n",
    "    \"\"\"Third LLM call for final polish\"\"\"\n",
    "\n",
    "    msg = llm.invoke(f\"Add a surprising twist to this joke: {state['improved_joke']}\")\n",
    "    return {\"final_joke\": msg.content}\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Build workflow\n",
    "workflow = StateGraph(State)\n",
    "\n",
    "# Add nodes\n",
    "workflow.add_node(\"generate_joke\", generate_joke)\n",
    "workflow.add_node(\"improve_joke\", improve_joke)\n",
    "workflow.add_node(\"polish_joke\", polish_joke)\n",
    "\n",
    "# Add edges to connect nodes\n",
    "workflow.add_edge(START, \"generate_joke\")\n",
    "workflow.add_conditional_edges(\n",
    "    \"generate_joke\", check_punchline, {\"Fail\": \"improve_joke\", \"Pass\": END}\n",
    ")\n",
    "workflow.add_edge(\"improve_joke\", \"polish_joke\")\n",
    "workflow.add_edge(\"polish_joke\", END)\n",
    "\n",
    "# Compile\n",
    "chain = workflow.compile()\n",
    "\n",
    "# Show workflow\n",
    "display(Image(chain.get_graph().draw_mermaid_png()))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Initial joke:\n",
      "Why did the cat join a band?\n",
      "\n",
      "Because it wanted to be the purr-cussionist.\n",
      "\n",
      "--- --- ---\n",
      "\n",
      "Improved joke:\n",
      "Here's an attempt at adding wordplay:\n",
      "\n",
      "Why did the cat join a band?\n",
      "\n",
      "Because it heard the drums were 'paw-some' and wanted to become the purr-cussionist – but little did it know, it was just the cat's meow on stage!\n",
      "\n",
      "In this version, I've added a few layers of wordplay:\n",
      "\n",
      "1. \"Paw-some\" is a play on the word \"awesome\" that incorporates the idea of a cat's paw.\n",
      "2. The phrase \"the cat's meow\" is an idiom that means something or someone is excellent or desirable, but in this context, it's also a clever pun on the fact that cats are known for their distinctive meowing sound.\n",
      "\n",
      "Let me know if you'd like me to try any further adjustments!\n",
      "\n",
      "--- --- ---\n",
      "\n",
      "Final joke:\n",
      "I love where you're going with this joke. Here's a suggestion for adding another layer of wordplay:\n",
      "\n",
      "Why did the cat join a band?\n",
      "\n",
      "Because it heard the drums were 'paw-some' and wanted to become the purr-cussionist – but little did it know, it was just the cat's meow on stage! And after all that fame, the cat's whiskers were ruffled by the attention.\n",
      "\n",
      "In this revised version:\n",
      "\n",
      "1. I've added a new layer of wordplay with \"ruffled by the attention,\" which is a play on words referencing both the cat's feathers (whiskers) and being emotionally stirred or flustered.\n",
      "2. This addition maintains the lighthearted tone while further exploring the comedic potential of the joke.\n",
      "\n",
      "Let me know if you'd like to experiment with other adjustments!\n"
     ]
    }
   ],
   "source": [
    "# Invoke\n",
    "state = chain.invoke({\"topic\": \"cats\"})\n",
    "print(\"Initial joke:\")\n",
    "print(state[\"joke\"])\n",
    "print(\"\\n--- --- ---\\n\")\n",
    "if \"improved_joke\" in state:\n",
    "    print(\"Improved joke:\")\n",
    "    print(state[\"improved_joke\"])\n",
    "    print(\"\\n--- --- ---\\n\")\n",
    "\n",
    "    print(\"Final joke:\")\n",
    "    print(state[\"final_joke\"])\n",
    "else:\n",
    "    print(\"Joke failed quality gate - no punchline detected!\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Rough RRA Workflow - Prompt Chaining"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "#memory = MemorySaver()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Graph state\n",
    "class State(TypedDict):\n",
    "    user_proposal: str\n",
    "    risk_assessment_and_rating: str\n",
    "    proposal_feedback: str\n",
    "    improved_proposal: str"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "llm = ChatOllama(\n",
    "    model=LLM_CONFIGS[\"llama3.2\"][\"model\"]\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Nodes\n",
    "def risk_assessment(state: State):\n",
    "    \"\"\"First LLM call to provide a risk assessment of the user proposal\"\"\"\n",
    "\n",
    "    msg = llm.invoke(\n",
    "        [\n",
    "            SystemMessage(content=\"You are a FDA regulatory reviewer. Provide a risk \\\n",
    "                assessment of the user submission and detail specific flaws in the application\\\n",
    "                    that would not pass regulatory approval. Provide an overall summary and a rating \\\n",
    "                        from 1 to 10.\"),\n",
    "            HumanMessage(content=f\"Review this proposal and provide a rating: {state['user_proposal']}\")\n",
    "        ]\n",
    "    )\n",
    "    \n",
    "    return {\"risk_assessment_and_rating\": msg.content}\n",
    "\n",
    "\n",
    "def check_rating(state: State):\n",
    "    \"\"\"Gate function to check if the risk rating is = 5 out of 10\"\"\"\n",
    "\n",
    "    # Simple check - does the joke contain \"?\" or \"!\"\n",
    "    if \"5\" in state[\"risk_assessment_and_rating\"]:\n",
    "        return \"Fail\"\n",
    "    return \"Pass\"\n",
    "\n",
    "\n",
    "def regulatory_risk_critquer(state: State):\n",
    "    \"\"\"Second LLM call to provide specific feedback based on different categories of regulatory approval to improve the rating.\"\"\"\n",
    "\n",
    "    #msg = llm.invoke(f\"Make this joke funnier by adding wordplay: {state['joke']}\")\n",
    "    msg = llm.invoke(\n",
    "        [\n",
    "            SystemMessage(content=\"You are an expert regulatory critiquer. \\\n",
    "                            Given the risk assessment and rating, propose \\\n",
    "                                changes and explain why to make these changes to improve the original proposal.\\\n",
    "                                Also provide an alternative approach for how they can rework their proposal to a different population or other strategies you can think of for better success \\\n",
    "                                    Give the final result in bullet points summary for each of these categories. \\\n",
    "                                    1) Mechanistic Risk 2) Biomarker Asessment 3) Endpoint Alignment 4) Safety.\"),\n",
    "            HumanMessage(content=f\"Here is the original proposal: {state['user_proposal']}. Here is the risk assessment \\\n",
    "                and rating: {state['risk_assessment_and_rating']}\")\n",
    "        ]\n",
    "    )\n",
    "    return {\"proposal_feedback\": msg.content}\n",
    "\n",
    "\n",
    "def proposal_writer(state: State):\n",
    "    \"\"\"Third LLM call for writing a new proposal based on feedback.\"\"\"\n",
    "\n",
    "    #msg = llm.invoke(f\"Add a surprising twist to this joke: {state['improved_joke']}\")\n",
    "    msg = llm.invoke(\n",
    "        [\n",
    "            SystemMessage(content=\"You are an expert FDA regulatory writer. \\\n",
    "                            Given the feedback for approval, rewrite the original proposal with the appropriate changes. \\\n",
    "                                Provide a 200-word new proposal well-written incorporating the changes\"),\n",
    "            HumanMessage(content=f\"Here is the original proposal: {state['user_proposal']}. Here is the risk assessment \\\n",
    "                and rating: {state['risk_assessment_and_rating']}. Here is the proposal feedback: {state['proposal_feedback']}\")\n",
    "        ]\n",
    "    )\n",
    "    return {\"improved_proposal\": msg.content}\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Build workflow\n",
    "workflow = StateGraph(State)\n",
    "\n",
    "# Add nodes\n",
    "workflow.add_node(\"risk_assessment\", risk_assessment)\n",
    "workflow.add_node(\"regulatory_risk_critquer\", regulatory_risk_critquer)\n",
    "workflow.add_node(\"proposal_writer\", proposal_writer)\n",
    "\n",
    "# Add edges to connect nodes\n",
    "workflow.add_edge(START, \"risk_assessment\")\n",
    "workflow.add_conditional_edges(\n",
    "    \"risk_assessment\", check_rating, {\"Fail\": \"regulatory_risk_critquer\", \"Pass\": END}\n",
    ")\n",
    "workflow.add_edge(\"regulatory_risk_critquer\", \"proposal_writer\")\n",
    "workflow.add_edge(\"proposal_writer\", END)\n",
    "\n",
    "# Compile\n",
    "chain = workflow.compile()\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "ename": "ValueError",
     "evalue": "Failed to reach https://mermaid.ink/ API while trying to render your graph. Status code: 502.\n\nTo resolve this issue:\n1. Check your internet connection and try again\n2. Try with higher retry settings: `draw_mermaid_png(..., max_retries=5, retry_delay=2.0)`\n3. Use the Pyppeteer rendering method which will render your graph locally in a browser: `draw_mermaid_png(..., draw_method=MermaidDrawMethod.PYPPETEER)`",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mValueError\u001b[39m                                Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[15]\u001b[39m\u001b[32m, line 2\u001b[39m\n\u001b[32m      1\u001b[39m \u001b[38;5;66;03m# Show workflow\u001b[39;00m\n\u001b[32m----> \u001b[39m\u001b[32m2\u001b[39m display(Image(\u001b[43mchain\u001b[49m\u001b[43m.\u001b[49m\u001b[43mget_graph\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\u001b[43m.\u001b[49m\u001b[43mdraw_mermaid_png\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m))\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/GitHub/aicompdrug/LLMFineTuning/rragent-reet/lib/python3.11/site-packages/langchain_core/runnables/graph.py:685\u001b[39m, in \u001b[36mGraph.draw_mermaid_png\u001b[39m\u001b[34m(self, curve_style, node_colors, wrap_label_n_words, output_file_path, draw_method, background_color, padding, max_retries, retry_delay, frontmatter_config)\u001b[39m\n\u001b[32m    677\u001b[39m \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34;01mlangchain_core\u001b[39;00m\u001b[34;01m.\u001b[39;00m\u001b[34;01mrunnables\u001b[39;00m\u001b[34;01m.\u001b[39;00m\u001b[34;01mgraph_mermaid\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;28;01mimport\u001b[39;00m draw_mermaid_png\n\u001b[32m    679\u001b[39m mermaid_syntax = \u001b[38;5;28mself\u001b[39m.draw_mermaid(\n\u001b[32m    680\u001b[39m     curve_style=curve_style,\n\u001b[32m    681\u001b[39m     node_colors=node_colors,\n\u001b[32m    682\u001b[39m     wrap_label_n_words=wrap_label_n_words,\n\u001b[32m    683\u001b[39m     frontmatter_config=frontmatter_config,\n\u001b[32m    684\u001b[39m )\n\u001b[32m--> \u001b[39m\u001b[32m685\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mdraw_mermaid_png\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    686\u001b[39m \u001b[43m    \u001b[49m\u001b[43mmermaid_syntax\u001b[49m\u001b[43m=\u001b[49m\u001b[43mmermaid_syntax\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    687\u001b[39m \u001b[43m    \u001b[49m\u001b[43moutput_file_path\u001b[49m\u001b[43m=\u001b[49m\u001b[43moutput_file_path\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    688\u001b[39m \u001b[43m    \u001b[49m\u001b[43mdraw_method\u001b[49m\u001b[43m=\u001b[49m\u001b[43mdraw_method\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    689\u001b[39m \u001b[43m    \u001b[49m\u001b[43mbackground_color\u001b[49m\u001b[43m=\u001b[49m\u001b[43mbackground_color\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    690\u001b[39m \u001b[43m    \u001b[49m\u001b[43mpadding\u001b[49m\u001b[43m=\u001b[49m\u001b[43mpadding\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    691\u001b[39m \u001b[43m    \u001b[49m\u001b[43mmax_retries\u001b[49m\u001b[43m=\u001b[49m\u001b[43mmax_retries\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    692\u001b[39m \u001b[43m    \u001b[49m\u001b[43mretry_delay\u001b[49m\u001b[43m=\u001b[49m\u001b[43mretry_delay\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    693\u001b[39m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/GitHub/aicompdrug/LLMFineTuning/rragent-reet/lib/python3.11/site-packages/langchain_core/runnables/graph_mermaid.py:293\u001b[39m, in \u001b[36mdraw_mermaid_png\u001b[39m\u001b[34m(mermaid_syntax, output_file_path, draw_method, background_color, padding, max_retries, retry_delay)\u001b[39m\n\u001b[32m    287\u001b[39m     img_bytes = asyncio.run(\n\u001b[32m    288\u001b[39m         _render_mermaid_using_pyppeteer(\n\u001b[32m    289\u001b[39m             mermaid_syntax, output_file_path, background_color, padding\n\u001b[32m    290\u001b[39m         )\n\u001b[32m    291\u001b[39m     )\n\u001b[32m    292\u001b[39m \u001b[38;5;28;01melif\u001b[39;00m draw_method == MermaidDrawMethod.API:\n\u001b[32m--> \u001b[39m\u001b[32m293\u001b[39m     img_bytes = \u001b[43m_render_mermaid_using_api\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    294\u001b[39m \u001b[43m        \u001b[49m\u001b[43mmermaid_syntax\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    295\u001b[39m \u001b[43m        \u001b[49m\u001b[43moutput_file_path\u001b[49m\u001b[43m=\u001b[49m\u001b[43moutput_file_path\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    296\u001b[39m \u001b[43m        \u001b[49m\u001b[43mbackground_color\u001b[49m\u001b[43m=\u001b[49m\u001b[43mbackground_color\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    297\u001b[39m \u001b[43m        \u001b[49m\u001b[43mmax_retries\u001b[49m\u001b[43m=\u001b[49m\u001b[43mmax_retries\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    298\u001b[39m \u001b[43m        \u001b[49m\u001b[43mretry_delay\u001b[49m\u001b[43m=\u001b[49m\u001b[43mretry_delay\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    299\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    300\u001b[39m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[32m    301\u001b[39m     supported_methods = \u001b[33m\"\u001b[39m\u001b[33m, \u001b[39m\u001b[33m\"\u001b[39m.join([m.value \u001b[38;5;28;01mfor\u001b[39;00m m \u001b[38;5;129;01min\u001b[39;00m MermaidDrawMethod])\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/GitHub/aicompdrug/LLMFineTuning/rragent-reet/lib/python3.11/site-packages/langchain_core/runnables/graph_mermaid.py:450\u001b[39m, in \u001b[36m_render_mermaid_using_api\u001b[39m\u001b[34m(mermaid_syntax, output_file_path, background_color, file_type, max_retries, retry_delay)\u001b[39m\n\u001b[32m    445\u001b[39m     \u001b[38;5;66;03m# For other status codes, fail immediately\u001b[39;00m\n\u001b[32m    446\u001b[39m     msg = (\n\u001b[32m    447\u001b[39m         \u001b[33m\"\u001b[39m\u001b[33mFailed to reach https://mermaid.ink/ API while trying to render \u001b[39m\u001b[33m\"\u001b[39m\n\u001b[32m    448\u001b[39m         \u001b[33mf\u001b[39m\u001b[33m\"\u001b[39m\u001b[33myour graph. Status code: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mresponse.status_code\u001b[38;5;132;01m}\u001b[39;00m\u001b[33m.\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[33m\"\u001b[39m\n\u001b[32m    449\u001b[39m     ) + error_msg_suffix\n\u001b[32m--> \u001b[39m\u001b[32m450\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(msg)\n\u001b[32m    452\u001b[39m \u001b[38;5;28;01mexcept\u001b[39;00m (requests.RequestException, requests.Timeout) \u001b[38;5;28;01mas\u001b[39;00m e:\n\u001b[32m    453\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m attempt < max_retries:\n\u001b[32m    454\u001b[39m         \u001b[38;5;66;03m# Exponential backoff with jitter\u001b[39;00m\n",
      "\u001b[31mValueError\u001b[39m: Failed to reach https://mermaid.ink/ API while trying to render your graph. Status code: 502.\n\nTo resolve this issue:\n1. Check your internet connection and try again\n2. Try with higher retry settings: `draw_mermaid_png(..., max_retries=5, retry_delay=2.0)`\n3. Use the Pyppeteer rendering method which will render your graph locally in a browser: `draw_mermaid_png(..., draw_method=MermaidDrawMethod.PYPPETEER)`"
     ]
    }
   ],
   "source": [
    "# Show workflow\n",
    "display(Image(chain.get_graph().draw_mermaid_png()))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Initial review:\n",
      "**Risk Assessment and Flaws:**\n",
      "\n",
      "1. **Lack of detailed mechanistic information**: The proposal does not provide sufficient evidence on the specific mechanisms by which Respilimab reduces eosinophilic asthma symptoms. A clear explanation of how the antibody works is essential to understand its therapeutic effects.\n",
      "2. **Insufficient data on adverse events**: The proposal only mentions safety data without providing a comprehensive analysis of adverse event profiles, including frequency, severity, and potential long-term consequences. This omission raises concerns about the potential risks associated with Respilimab use.\n",
      "3. **Inadequate comparisons to existing treatments**: The trial outcomes are presented as isolated results, but the proposal does not adequately compare Respilimab to established treatments for eosinophilic asthma, such as omalizumab or mepolizumab. A thorough comparison would help demonstrate its unique benefits and risks.\n",
      "4. **Unclear patient population characteristics**: The proposal does not provide sufficient information on the demographics, comorbidities, and other relevant factors that might influence Respilimab's efficacy and safety in this patient population. This lack of detail could lead to concerns about generalizability.\n",
      "5. **Lack of discussion on potential interactions with concomitant medications**: The proposal does not address potential interactions between Respilimab and other medications commonly used in asthma management, such as corticosteroids or bronchodilators. This oversight could increase the risk of adverse reactions.\n",
      "\n",
      "**Overall Summary:**\n",
      "\n",
      "The proposed FDA label for Respilimab is lacking in key areas that would be essential to support regulatory approval. While the trial outcomes demonstrate promise, the proposal's shortcomings raise concerns about the safety and efficacy of this monoclonal antibody. To address these issues, additional data on mechanisms of action, adverse event profiles, comparisons to existing treatments, patient population characteristics, and potential interactions with concomitant medications would be necessary.\n",
      "\n",
      "**Rating: 4/10**\n",
      "\n",
      "The rating is based on the following criteria:\n",
      "\n",
      "* Mechanistic information: 2/5\n",
      "* Safety data: 3/5\n",
      "* Comparison to existing treatments: 2.5/5\n",
      "* Patient population characteristics: 3/5\n",
      "* Potential interactions with concomitant medications: 2/5\n",
      "* Overall presentation and organization: 4/5\n",
      "\n",
      "These scores reflect the proposal's limitations in addressing key regulatory requirements, but also acknowledge the potential therapeutic benefits of Respilimab.\n",
      "\n",
      "--- --- ---\n",
      "\n",
      "proposal_feedback:\n",
      "Based on the original proposal and risk assessment report, I propose the following changes to improve the proposal:\n",
      "\n",
      "**Mechanistic Risk:**\n",
      "\n",
      "* Add a detailed section on the mechanism of action of Respilimab, including:\n",
      "\t+ The specific binding site on IL-13\n",
      "\t+ The structural characteristics of the antibody that enable its interaction with IL-13\n",
      "\t+ The proposed mechanisms by which Respilimab reduces eosinophilic asthma symptoms (e.g., reduction in IL-13-dependent inflammation)\n",
      "* Include a discussion on potential mechanisms for resistance or tolerance to Respilimab, and propose strategies to address these issues\n",
      "* Provide a comparison of the mechanism of action of Respilimab to existing treatments for eosinophilic asthma\n",
      "\n",
      "**Biomarker Assessment:**\n",
      "\n",
      "* Develop and validate biomarkers for the efficacy and safety of Respilimab, including:\n",
      "\t+ IL-13 levels in blood or sputum\n",
      "\t+ Eosinophil counts in blood or sputum\n",
      "\t+ Lung function tests (e.g., FEV1)\n",
      "\t+ Clinical outcomes measures (e.g., symptom questionnaires)\n",
      "* Present data on the correlation between biomarker responses and clinical outcomes, including:\n",
      "\t+ Correlation coefficients\n",
      "\t+ P-values for significance testing\n",
      "\t+ Confidence intervals for regression coefficients\n",
      "\n",
      "**Endpoint Alignment:**\n",
      "\n",
      "* Align Respilimab's endpoints with those used in existing treatments for eosinophilic asthma, such as:\n",
      "\t+ Reduction in symptoms (e.g., use of rescue medication)\n",
      "\t+ Improvement in lung function tests (e.g., FEV1)\n",
      "\t+ Decrease in exacerbation frequency or severity\n",
      "* Compare Respilimab's efficacy to existing treatments using standardized endpoints and statistical methods\n",
      "\n",
      "**Safety:**\n",
      "\n",
      "* Conduct a thorough review of adverse event data, including:\n",
      "\t+ Frequency and severity of adverse events\n",
      "\t+ Potential long-term consequences of adverse events\n",
      "\t+ Relationship between adverse events and dose, duration of treatment, or patient demographics\n",
      "* Include discussion on potential interactions with concomitant medications, such as corticosteroids or bronchodilators\n",
      "* Develop a risk management plan for Respilimab, including strategies for monitoring and managing adverse events\n",
      "\n",
      "**Alternative Approach:**\n",
      "\n",
      "For populations that may not be well-represented in the original trial (e.g., pediatric patients, patients with comorbidities), consider the following:\n",
      "\n",
      "* Conduct separate trials or sub-studies to evaluate Respilimab's efficacy and safety in these populations\n",
      "* Use surrogate endpoints (e.g., biomarkers) to monitor treatment response in these populations\n",
      "* Develop a strategy for adapting the dosing regimen or formulation of Respilimab based on patient age, weight, or other demographic factors\n",
      "\n",
      "**Summary:**\n",
      "\n",
      "Here is a bullet point summary of the proposed changes:\n",
      "\n",
      "Mechanistic Risk:\n",
      "\n",
      "* Add detailed mechanism-of-action information\n",
      "* Discuss potential mechanisms for resistance or tolerance\n",
      "* Compare with existing treatments\n",
      "\n",
      "Biomarker Assessment:\n",
      "\n",
      "* Develop and validate biomarkers for efficacy and safety\n",
      "* Present data on correlation between biomarker responses and clinical outcomes\n",
      "\n",
      "Endpoint Alignment:\n",
      "\n",
      "* Align Respilimab's endpoints with those used in existing treatments\n",
      "* Compare efficacy to existing treatments using standardized endpoints and statistical methods\n",
      "\n",
      "Safety:\n",
      "\n",
      "* Conduct thorough review of adverse event data\n",
      "* Discuss potential interactions with concomitant medications\n",
      "* Develop risk management plan for Respilimab\n",
      "\n",
      "Alternative Approach:\n",
      "\n",
      "* Separate trials or sub-studies for pediatric patients or patients with comorbidities\n",
      "* Use surrogate endpoints to monitor treatment response in these populations\n",
      "* Adapt dosing regimen or formulation based on patient demographics\n",
      "\n",
      "--- --- ---\n",
      "\n",
      "improved_proposal:\n",
      "Here is a rewritten version of the original proposal, incorporating the changes and feedback provided:\n",
      "\n",
      "**Respilimab: A Humanized Monoclonal Antibody for Treatment of Moderate-to-Severe Eosinophilic Asthma**\n",
      "\n",
      "**Introduction:**\n",
      "Respilimab is a humanized monoclonal antibody targeting IL-13, designed to treat moderate-to-severe eosinophilic asthma. This proposed FDA label outlines the dosing regimen (300 mg subcutaneous every 4 weeks), safety data, and trial outcomes demonstrating improved lung function and reduced exacerbations.\n",
      "\n",
      "**Mechanism of Action:**\n",
      "Respilimab binds specifically to IL-13, a key player in eosinophilic inflammation. The antibody's structural characteristics enable it to block the interaction between IL-13 and its receptors, thereby reducing eosinophilic inflammation and improving asthma symptoms. Additional mechanisms of action include:\n",
      "\n",
      "* Reduction in IL-13-dependent inflammation\n",
      "* Suppression of inflammatory cytokine release\n",
      "* Inhibition of eosinophil activation\n",
      "\n",
      "A comparison with existing treatments for eosinophilic asthma is presented below.\n",
      "\n",
      "**Biomarker Assessment:**\n",
      "Development of biomarkers for efficacy and safety is essential to understand Respilimab's therapeutic effects. The proposed biomarkers include:\n",
      "\n",
      "* IL-13 levels in blood or sputum\n",
      "* Eosinophil counts in blood or sputum\n",
      "* Lung function tests (e.g., FEV1)\n",
      "* Clinical outcomes measures (e.g., symptom questionnaires)\n",
      "\n",
      "Data on the correlation between biomarker responses and clinical outcomes are presented below.\n",
      "\n",
      "**Endpoint Alignment:**\n",
      "Respilimab's endpoints align with those used in existing treatments for eosinophilic asthma, including:\n",
      "\n",
      "* Reduction in symptoms (e.g., use of rescue medication)\n",
      "* Improvement in lung function tests (e.g., FEV1)\n",
      "* Decrease in exacerbation frequency or severity\n",
      "\n",
      "Comparison to existing treatments using standardized endpoints and statistical methods is presented below.\n",
      "\n",
      "**Safety:**\n",
      "A thorough review of adverse event data indicates that Respilimab is generally safe, with a low incidence of severe adverse events. Potential interactions with concomitant medications are discussed below.\n",
      "\n",
      "**Potential Interactions with Concomitant Medications:**\n",
      "Respilimab may interact with concomitant medications commonly used in asthma management, such as corticosteroids or bronchodilators. Strategies for monitoring and managing these interactions include:\n",
      "\n",
      "* Regular monitoring of IL-13 levels\n",
      "* Adjusting dosing regimens based on patient demographics\n",
      "\n",
      "**Risk Management Plan:**\n",
      "A risk management plan is proposed to address potential adverse events associated with Respilimab use.\n",
      "\n",
      "* Strategy 1: Monitoring and management of adverse events\n",
      "* Strategy 2: Dose adjustments based on patient demographics\n",
      "* Strategy 3: Development of new treatments for patients who do not respond to Respilimab\n",
      "\n",
      "**Alternative Approach:**\n",
      "For populations that may not be well-represented in the original trial (e.g., pediatric patients, patients with comorbidities), consider separate trials or sub-studies to evaluate Respilimab's efficacy and safety.\n",
      "\n",
      "Summary:\n",
      "The proposed FDA label for Respilimab provides a comprehensive overview of its mechanism of action, biomarker assessment, endpoint alignment, safety profile, and risk management plan. The inclusion of detailed mechanisms of action, biomarkers, and potential interactions with concomitant medications enhances the label's completeness and accuracy.\n"
     ]
    }
   ],
   "source": [
    "# Invoke\n",
    "user_prompt = \"This proposed FDA label describes Respilimab, a humanized monoclonal antibody \\\n",
    "    targeting IL-13, for treatment of moderate-to-severe eosinophilic asthma. It outlines dosing \\\n",
    "        (300 mg subcutaneous every 4 weeks), safety data, and trial outcomes showing improved lung \\\n",
    "            function and reduced exacerbations, supporting use in patients uncontrolled on standard inhaled therapies.\"\n",
    "\n",
    "state = chain.invoke({\"user_proposal\": user_prompt})\n",
    "print(\"Initial review:\")\n",
    "print(state[\"risk_assessment_and_rating\"])\n",
    "print(\"\\n--- --- ---\\n\")\n",
    "if \"proposal_feedback\" in state:\n",
    "    print(\"proposal_feedback:\")\n",
    "    print(state[\"proposal_feedback\"])\n",
    "    print(\"\\n--- --- ---\\n\")\n",
    "\n",
    "    print(\"improved_proposal:\")\n",
    "    print(state[\"improved_proposal\"])\n",
    "else:\n",
    "    print(\"Proposal failed quality gate - lower than 5 threshold!\")\n",
    "    \n",
    "    \n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "rragent-reet",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
